|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2005-9-6
|
|
pubmed:abstractText |
More children are coming to heart transplantation on extracorporeal membrane oxygenation (ECMO), or inotropic support and/or with renal impairment. The use of basiliximab, a chimeric monoclonal antibody against CD25 (interleukin 2 receptor alfa) has not been previously reported in critically ill pediatric heart transplant recipients. Basiliximab has potential advantages in the treatment of patients with renal impairment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adaptor Proteins, Signal Transducing,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/CABIN1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Calcineurin,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Tacrolimus,
http://linkedlifedata.com/resource/pubmed/chemical/basiliximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1557-3117
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1284-8
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16143246-Adaptor Proteins, Signal Transducing,
pubmed-meshheading:16143246-Adolescent,
pubmed-meshheading:16143246-Antibodies, Monoclonal,
pubmed-meshheading:16143246-Calcineurin,
pubmed-meshheading:16143246-Child,
pubmed-meshheading:16143246-Child, Preschool,
pubmed-meshheading:16143246-Cyclosporine,
pubmed-meshheading:16143246-Extracorporeal Membrane Oxygenation,
pubmed-meshheading:16143246-Female,
pubmed-meshheading:16143246-Graft Rejection,
pubmed-meshheading:16143246-Heart Transplantation,
pubmed-meshheading:16143246-Humans,
pubmed-meshheading:16143246-Immunosuppressive Agents,
pubmed-meshheading:16143246-Infant,
pubmed-meshheading:16143246-Kidney,
pubmed-meshheading:16143246-Kidney Diseases,
pubmed-meshheading:16143246-Male,
pubmed-meshheading:16143246-Phosphoproteins,
pubmed-meshheading:16143246-Receptors, Interleukin-2,
pubmed-meshheading:16143246-Recombinant Fusion Proteins,
pubmed-meshheading:16143246-Tacrolimus
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Initial data on basiliximab in critically ill children undergoing heart transplantation.
|
|
pubmed:affiliation |
Pharmacy Department, Great Ormond Street Hospital for Children, London, United Kingdom. fordk2@gosh.nhs.uk
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
